Hemostemix Receives FDA Support for Its Basket Protocol Approach
Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, announces the successful completion of its pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administra
Biotechnology, Pharmaceuticals, Health
2026-01-16 12:26 PM EST | Hemostemix Inc.
LIS Technologies Inc. to Invest $1.38 Billion in Oak Ridge, Tennessee Following Its Acquisition of $8 Million, 206-Acre Duct Island, Now Rebranded as "LIST Island"
Oak Ridge, Tennessee--(Newsfile Corp. - January 16, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, alongside Tennessee Gov. Bill Lee and Deputy Gov. and Department of Economic and Community Development Commissioner Stuart C. McWhorter, today announced LIST will create 203 jobs and invest $1.38 billion in its future flagship commercial scale laser-
Technology, Mining and Metals, Energy, Health
2026-01-16 10:07 AM EST | LIS Technologies Inc.
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole underwriter and sole bookrunner pursuant to which the underwriter (the "Underwriter") has agreed to purchase for resale 10,384,616
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:46 AM EST | Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord Genuity Corp. (the "Underwriter") as the sole underwriter and sole bookrunner pursuant to which the Underwriter has agreed to p
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-16 8:42 AM EST | Cardiol Therapeutics Inc.
Optimi Health Announces Equity Incentive Grants and Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced a series of equity compensation and marketing initiatives designed to support its growth strategy and enhance market awareness. Equity Incentive Grants Optimi announces that, pursuant to its equity incentive plan and subject
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-16 7:00 AM EST | Optimi Health Corp.
Psyched Wellness Sells Out of First Run of Calmer and Announces New Production Run
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched" or the "Company"), a life sciences company dedicated to developing and commercializing products derived from the Amanita Muscaria mushroom, is pleased to announce a key commercial milestone for its newest product, Calmer. The Company has officially sold out of its initial production run following strong early demand and positive consumer feedback.
Cannabis, Health, Psychedelics, Cannabis Manufacturer
2026-01-15 12:42 PM EST | Psyched Wellness Ltd.
Adia Nutrition Promotes Emmanuela Derisbrun, APRN, FNP-C, to Provider Role Amid Growing Patient Demand and Launch of Autism IRB Study
Winter Park, Florida--(Newsfile Corp. - January 15, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in advanced regenerative therapies, announces that Emmanuela Derisbrun, APRN, FNP-C, has transitioned from subcontractor to employed provider. This move supports rising patient volume and the launch of Adia Med's IRB-approved autism spectrum disorder regenerative study.
Healthcare and Hospitals, Health
2026-01-15 11:03 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-15 8:45 AM EST | Phio Pharmaceuticals Corp.
Predictmedix AI Inc. Selected by Canadian Government for Mexico Trade Mission, Led by Minister Dominic LeBlanc, to Drive Growth and High-Value Partnerships
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), a pioneering leader in artificial intelligence-enabled health and safety technology, proudly announces its highly selective inclusion in the Official Canada Trade Mission to Mexico, scheduled for February 15–20, 2026, with key activities centered in Mexico City, Guadalajara, and Monterrey. This elite delegation brings together on
2026-01-15 7:03 AM EST | Predictmedix AI Inc.
Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) ("Scryb'' or the "Company"), is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer" or "Cybeats"). Scryb's total share ownership position of Cybeats is unchanged following all transactions outlined in this press release. Scryb outlines below that it accepted common shares in lieu of cash repayment from Cybeats Techno
Biotechnology, Healthcare and Hospitals, Health
2026-01-14 9:08 PM EST | Scryb Inc.
LIS Technologies Inc. Appoints 25 Year Plus Veteran and Distinguished U.S. National Laboratory Leader Dr. Kirk D. Rector as Director of its Medical and Stable Isotopes
Oak Ridge, Tennessee--(Newsfile Corp. - January 14, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that Kirk D. Rector, Ph.D., has been appointed as its Director of Medical and Stable Isotopes. Dr. Kirk D. Rector is a physical chemist and technology leader with more than twenty-five years of experience spanning medical and stable is
Technology, Mining and Metals, Energy, Health
2026-01-14 8:29 AM EST | LIS Technologies Inc.
Optimi Health to Present at the Sidoti Micro-Cap Conference on January 21-22, 2026
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a leading producer of prescribed psychedelic treatments for mental health therapies, today announced that management has been invited to present at the Sidoti Micro-Cap Virtual Conference on January 21-22, 2026. Chief Executive Officer Dane Stevens is scheduled to host virtual one-on-one meetings with institutional invest
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-01-14 7:30 AM EST | Optimi Health Corp.
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Highlights ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment Supports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverage Establishe
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-14 2:00 AM EST | TempraMed Technologies Ltd
Adia Med Kicks Off Recruitment Today for Innovative Autism Stem Cell Study
Winter Park, Florida--(Newsfile Corp. - January 13, 2026) - ADIA Nutrition Inc. (OTCQB: ADIA), today announced that its subsidiary, Adia Med of Winter Park, LLC., has officially begun the recruitment process for a groundbreaking clinical study evaluating the potential benefits of stem cell therapy in children with Autism Spectrum Disorder (ASD). The 24-month randomized interventional study, officially titled "Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study" and list
Healthcare and Hospitals, Health
2026-01-13 10:16 AM EST | Adia Nutrition Inc.
The State of HTM, 2025: Report Signals Changing Health Tech Workforce
Arlington, Virginia--(Newsfile Corp. - January 13, 2026) - Approximately 1000 healthcare technology management (HTM) professionals across North America have participated in an expansive survey of their field. The insights of these essential healthcare personnel —including BMETs, clinical engineers, and management staff— resulted in the publicly available AAMI and TechNation 2025 State of HTM Report, which contains caus
2026-01-13 9:41 AM EST | Association for the Advancement of Medical Instrumentation
LIS Technologies Inc. Announces Fourth Consecutive Oversubscribed Funding Round of $17 Million, Totaling $64 Million to Revitalize the Only U.S.-Origin, Patented Laser Uranium Enrichment Technology to Support the Domestic Nuclear Fuel Cycle
Oak Ridge, Tennessee--(Newsfile Corp. - January 13, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that it has closed its 240% oversubscribed $17 Million funding round. The round attracted participation from a single large, accredited investor that accounted for the majority of initial raise, along with returning advanced nuclear technolo
Technology, Mining and Metals, Energy, Health
2026-01-13 8:59 AM EST | LIS Technologies Inc.
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - January 13, 2026) - Cardiol Therapeutics Inc. (NASDAQ:
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2026-01-13 7:27 AM EST | Cardiol Therapeutics Inc.
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each, a "Unit") at a price of $0.76 p
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-12 5:30 PM EST | TempraMed Technologies Ltd
Predictmedix AI Inc. Announces Proposed Name Change to QScreen AI Inc., Pioneering the Fusion of Quantum Computing and AI to Transform Healthcare
Toronto, Ontario--(Newsfile Corp. - January 12, 2026) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), excited to announce its proposed name change to QScreen AI Inc., with a new ticker symbol QAI, subject to regulatory approval. This strategic rebranding underscores the Company's evolution into a premier healthcare innovator, uniquely positioned at the intersection of artificial intelligence, quantum-inspired computing, and data-driven healt
2026-01-12 7:11 AM EST | Predictmedix AI Inc.
CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence
Houston, Texas--(Newsfile Corp. - January 12, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced today the launch of its Evidence Sprint 2026, an intensive execution phase designed to turn cannabinoid science into usable medical evidence: protocols, operational collaboration, and projects ready for competitive funding. CBIH confirms receipt of a communication from the Centers for Med
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-12 7:00 AM EST | Cannabis Bioscience International Holdings